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Biopsies of native or transplanted kidneys in patients suffering chronic or acute renal failure
are commonly stained for tissue examination and search for possible crystal deposits which
are then identiﬁed by polarizing microscopy and staining by von Kossa's method revealing
mainly calcium deposits. Renal biopsies presumably containing crystal deposits were
analyzed with a Spotlight 400 mFTIR (Fourier Transform Infra Red) imaging system in the
mid-infrared spectral range to obtain infrared maps of tissue slides at high spatial resolution,
down to 10 microns. When required, an optional ATR imaging accessory was used,
improving the spatial resolution by a factor four, down to 3 microns at 1000 cm1. Among
the 685 renal biopsies, 72% contained abnormal non-proteic material. Among them, 2.16%
contained drug crystals (triamterene, N-acetylsulfadiazine, ciproﬂoxacine, indinavir, ataza-
navir, foscarnet, and vancomycine). We focused on foscarnet and atazanavir deposits. In the
case of foscarnet-induced renal failure, two types of crystals were found in one patient. They
were located in different parts of the nephron: sodium and/or calcium phosphonoformate
crystals within glomerules and carbapatite in the proximal tubular cells. By contrast, ata-
zanavir was only found in the tubular lumen of the nephron.
A precise identiﬁcation of crystal deposits is essential for the diagnosis of an unexplained
renal failure. Common histological procedures clearly fail to identify crystals deposits
accurately. In most cases, light and polarizing microscopic examination should be
completed by FTIR analysis.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As assessed by several authors [1e3], renal dysfunction
and injury secondary to medications are common, and can
present as a subtle injury and/or overt renal failure. RenalC, Universite Paris-6,
Daudon).
ed by Elsevier Masson SAS.injury associated with drugs may involve several parts of
the kidney: glomeruli, tubules, interstitium and blood
vessels. Drug-induced acute renal failure (ARF) was re-
ported to account for 20% of all ARF cases [4]. Drug-induced
nephrolithiasis accounts for 1e2% of all renal calculi [5].
Regarding children, C. Glanzmann et al. [6] have noticed
that some drugs are associated with acute renal dysfunc-
tion in pediatric intensive care, especially some critical
medication groups, such as betalactam antibiotics,This is an open access article under the CC BY-NC-ND license (http://
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tory drugs.
Among the different manifestations of drug-induced
nephrotoxicity, we can quote acidebase abnormalities,
electrolyte imbalances, urine sediment abnormalities,
proteinuria, pyuria, hematuria, and, most commonly, a
decline in the glomerular ﬁltration rate [2]. Different
mechanisms of drug-induced acute kidney injury (AKI) can
be described such as prerenal AKI, glomerulonephritis,
tubulopathies, interstitial nephritis, vascular nephropa-
thies, crystalluria, etc.
Numerous drugs including foscarnet, atazanavir, teno-
fovir [7], vancomycin [8], gentamicin [9], taxol [10],
cisplatin [11], and nucleotides [12] were reported as
nephrotoxic drugs. Among drugs that are able to induce
crystals or stones, we must distinguish between (1) poorly
soluble drugs with high urine excretion that favors crys-
tallization of the drug or its metabolites in urine and (2)
drugs that provoke urinary crystals and calculi as a conse-
quence of their metabolic effects [4,13e15]. In the two
cases, the chemical complexity of this particular etiology
i.e. the fact that drugs as well as their metabolites may be
involved calls for the use of physicochemical techniques
such as Fourier transform infrared microspectroscopy
(mFTIR) to identify accurately the substances accumulated
in the tissue [16,17].
The aim of this contribution is to assess the chemical
nature of drugs and their metabolites as well as their
localization in the kidney (presence in the glomerulus or in
the tubule). To attain this goal, a set of kidney biopsies has
been selected in order to consider nephrotoxicity by fos-
carnet and atazanavir. The chemical characterization of
abnormal deposits will be performed through vibrational
spectroscopies such mFTIR. The morphology of the deposits
at the micrometer scale will be described through Field
Emission Scanning Electron Microscopy (FE-SEM).
2. Materials and methods
2.1. Samples
685 kidney biopsies were investigated. The biological
samples came from various hospitals from France, Canada,
Belgium, Switzerland, Italy, and North Africa. All biopsies
were examined in Tenon Hospital (PariseFrance). Five
microns slices of the biopsies were deposited either on
CaF2 plates or on low-e microscope slides (MirrIR, Kevley
Technologies, Tienta Sciences, Indianapolis) in order to
perform mFTIR experiments. In the case of Raman obser-
vation, the samples were deposited on classical glass
supports used at the hospital. For tissue embedded in
parafﬁn, the parafﬁn was chemically removed in order to
improve the crystal detection under the microscope. Each
sample was only named by a study number, without
indication of the name of the patient or potential identi-
ﬁcation data.
2.2. Materials
As already described in a previous publication [18], a
part of the experiments (n¼24 biopsies) were carried out atSOLEIL-Synchrotron (Saint-Aubin, Gif-sur-Yvette, France)
on the SMIS beamline. The synchrotron radiation-mFTIR
mappings were collected in reﬂection mode using an
Infrared microscope (Thermo/Nicolet Nic-Plan) coupled to
a mFTIR spectrometer (Thermo Nicolet MAGNA-IR 550). The
IR microscope is equipped with a motorized sample stage
(precision 1 mm) and a liquid nitrogen cooled mercury
cadmium telluride (MCT e 250 mm) detector. Most of the
analysis and maps presented here were achieved with a
projected area on the sample of 6 6 mm2 and a step size of
6 mm, and each spectrum was acquired after 64 accumu-
lations at 8 cm1 spectral resolution. Data acquisition and
processing were performed using OMNIC software (Version
7.4, Thermo-Scientiﬁc). The compounds were identiﬁed by
comparing them to reference spectra [19].
IR microspectroscopy was performed on an IN10MX
microscope (Thermo Scientiﬁc) for recording large maps.
All spectra were collected in ultrafast mode using a
50 mm50 mm aperture. The spectra were collected in the
4000e700 cm1 mid-IR range at a resolution of 8 cm1
with one spectrum per pixel. Data analysis of IR spectra and
chemical images was performed using OMNIC software
(Thermo Scientiﬁc). Other biopsies were analyzed, in our
hospital department in the Service des Explorations Fonc-
tionnelles Multidisciplinaires (Tenon hospitale Paris), with
the Spotlight 400 FTIR imaging System in the mid-infrared
spectral range to obtain infrared maps of tissue slides at
high spatial resolution, down to 10 microns. When
required, an optional ATR imaging accessory was used,
improving the spatial resolution by a factor four, down to 3
microns at 1000 cm1.
3. Results and discussion
A very limited proportion of patients receiving drugs
develops crystalluria and, sometimes, acute renal failure
due to tubular obstruction by drug crystals. This suggests
that the formation of drug-induced crystal involves an
interplay of risk factors speciﬁc either of the drug itself
(high dose, high urinary excretion, low solubility product,
long-term treatment without supervision, size and crystal
forms) (Fig. 1) and of the patient (inadequate diuresis,
urinary stasis, antacids, uricosurics, anti inﬂammatory
drugs, urinary pH, and urinary tract infection) [20].
Drugs, which may crystallize in urine are not so
numerous [21] and belong to various pharmacological
groups: antibacterial drugs, protease inhibitors, analgesics,
antihypertensive agents, antacids, and some other drugs.
We found a number of these drugs in renal deposits. Note
that hypercalciuria and nephrolithiasis may result from
calcium supplements, especially when associated with
vitamin D [22].
At the hospital, the classical analysis procedure starts by
observation through optical microscope underlining the
presence of birefringent or non-refringent deposits. This
criterion is not sufﬁcient to ensure the precise identiﬁca-
tion of the compound. Several drugs are present as bire-
fringent crystals, namely triamterene, N-acetylsulfadiazine,
ciproﬂoxacine, indinavir, and atazanavir while others are
non-refringent, namely foscarnet or vancomycine. To
identify precisely the chemical nature of the drugs, mFTIR
Fig. 1. Risk factors of crystallization related to the drug and/or the patient.
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we identiﬁed in kidney tissue over the past thirty years are
summarized.
In this contribution, we focus on foscarnet (trisodium
salt of phosphonoformic acid) and atazanavir.3.1. Foscarnet
Foscarnet is a pyrophosphate analog of chemical for-
mula CH3O5P (Fig. 2) that exhibits a broad activity against
both DNA and RNA viruses and is considered standard
treatment against cytomegalovirus.
More precisely, this drug achieves its antiviral effect via
the inhibition of viral polymerases by preventingTable 1





Triamterene 1 Hydroxy-40-triamterene sulfate
Triamterene 2 Triamterene þ metabolites
Piridoxilate 1 Calcium oxalate monohydrate
Ciproﬂoxacine 1 Ciproﬂoxacine, magnesium salt
Sulfadiazine 1 N-acetylsulfadiazine
Vancomycine 1 Vancomycine
Naftidrofuryl oxalate 2 Calcium oxalate monohydrate
Indinavir sulfate 2 Indinavir monohydrate
Atazanavir sulfate 2 Atazanavir
Foscarnet 7 Foscarnet, calcium and/or
sodium salts, carbapatitepyrophosphate exchange [23]. The half life of the drug is
between 3 and 7 h. Foscarnet is theoretically non-
metabolized and excreted unchanged by the kidney.
Recently, D. Boutolleau et al. [24] have described the
emergence of cytomegalovirus resistance to foscarnet in a
54-year-old man receiving foscarnet salvage therapy
because of multidrug-resistant HIV-1 infection. One of the
major drawbacks of this drug is related to crystal depo-
sition. Even if such pathological calciﬁcation has been
observed in different organs, special attention has to be
paid to its presence in kidney [25].
Different investigations have been dedicated to the
nephrotoxicity of foscarnet [26,27]. G. Deray et al. have
shown that foscarnet is a highly nephrotoxic drug which
induces acute tubular necrosis [28]. More recently, A.
Wallin and A. Ryrfeldt have suggested that the toxic ef-
fects of foscarnet may be due to its ability to form poorlyFig. 2. Chemical formula of foscarnet.
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consequence is hypocalcemia and its clinical conse-
quences such as tetany [30]. Another adverse effect is the
crystallization of foscarnet salts. Indeed, while trisodium
foscarnet is water soluble, the molecule is able to chelate
metallic ions such as Ca2þ, Mg2þ, Fe2þ and Zn2þ and then
to form precipitates [31]. The ﬁrst case of foscarnet-
induced nephropathy was described in 1990 [32].
The kidney was the most affected organ, but neurologic
and systemic injuries also were observed. Histologic anal-
ysis of autopsied organs revealed precipitation of crystals
accompanied by granulomatous inﬂammatory reaction in
numerous tissues, including the kidney, pulmonary pa-
renchyma and esophageal and cardiac mucosa [25].Fig. 3. Foscarnet IR spectra display typical absorption bands at 1390, 1082 and 97
protein tissue (renal biopsy).In a previous publication [33], we have shown that even
in the very same biopsy different chemical phases can be
identiﬁed. Thus, we start our study by mFTIR experiments in
order to localize and identify the foscarnet deposits. Fos-
carnet deposits are identiﬁed through the presence of IR
absorption bands at 970 cm1 (Fig. 2). In a previous work, it
was reported that foscarnet deposits may be present as
different salts containing calcium and/or sodium ions [31].
Drugs have their own metabolism with a urinary excretion
of the unchanged drug. Due to its particular chemical for-
mula, foscarnet could be metabolized to form inorganic
phosphate within the cells as suspected by the accumula-
tion of apatite in the cells of the proximal tubule [18] in a
patient treated with that drug (Fig. 3).0 cm1. A: Optical image. B: Typical IR spectra of foscarnet and apatite in a
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gular shapes and are agglomerated to make abnormal large
deposits (Fig. 4). These deposits are present here in tubules
and not in glomeruli.Fig. 5. Chemical formula of atazanavir.3.2. Atazanavir
Several drugs against HIV may be the cause of renal
failure in patients under tritherapy. Indinavir was early
identiﬁed as a cause for kidney dysfunction [34] and neph-
rolithiasis mainly related to crystallization of the indinavir
monohydrate in urine [35] and kidney tubules [36]. Because
of its poor solubility in the normal urine pH range, the cause
of indinavir crystallization was related to its concentration
due to a short half-life (around 90 min) after oral adminis-
tration. Efavirenz was also reported sometimes as a cause of
nephrolithiasis [37,38]. Other molecules commonly used for
the treatment of HIV have been reported as nephrotoxic
[39e41]. Among them, atazanavir was reported as respon-
sible for acute interstitial nephritis [42,43]. With the with-
drawal of atazanavir, the renal impairment was reversible
with the selection of another anti-protease.
Atazanavir is a multicycle molecule (Fig. 5). It is a potent
and safe protease inhibitor with one daily administration
(300e400 mg per day).
Following a single 400-mg dose of 14C-atazanavir, 79% and
13% of the total radioactivity was recovered in the feces and
urine, respectively. Atazanavir is oxidized in the liver by the
cytochrome P450 enzymes and then converted as glucuro-
nide derivatives [44]. The two main ways for eliminating the
drug are the bile ducts and the kidney. The unchanged drug
accounts for approximately 20% and 7% of the administered
dose in the feces and urine, respectively [45]. Contrary to
indinavir, the half-life of atazanavir is around 7 h, thus
reducing the excretion peak of the drug in urine and the risk
for crystallization. However, atazanavir is now the main
substance responsible for drug-induced nephrolithiasis in our
country. The ﬁrst case of kidney stone was published in 2006
[46], followed by other reports [47]. A total of 30 cases were
reported by the FDA in the USA in 2007 [48]. In our experi-
ence, we identiﬁed atazanavir in 90 kidney stones analyzed inFig. 4. FE-SEM image of foscarnet crystals in tubules (renal biopsy).our laboratory between 2005 and 2016. Recently, we had the
opportunity to identify two other cases of atazanavir-induced
nephropathy. In the two biopsies, we were able to identify
atazanavir crystals by FTIR microscopy (Fig. 6).
FE-SEM images of atazanavir deposits are made of
needles or thin rod-shaped crystals aggregated in the
tubular lumen (Fig. 6).
Contrary to indinavir crystalluria and nephrolithiasis
observed in indinavir-treated patients that are explained by
physicochemical properties and pharmacokinetics of the
drug, the mechanism of atazanavir nephrotoxicity is un-
known. While indinavir crystalluria, which is highly uri-
nary pH-dependent, was found in 20% of 142 patients
treated by indinavir [49], atazanavir crystals were found in
the urine of only 9% of patients despite relatively high
concentrations in the urine compared to other drugs such
as lopinavir or ritonavir [50]. A longer exposure to ataza-
navir treatment was the unique factor identiﬁed to explain
crystalluria. However the pathogenic mechanism to
explain the incidence of renal colic and nephropathy in
atazanavir-treated patients is not clearly established [51]. It
has been proposed that as what happens in indinavir
calculi, the precipitation of atazanavir in renal tubules may
be the main cause, as a consequence of the fact that 7% of
atazanavir and 20% of indinavir are excreted unchanged in
urine unlike the other HIV drugs. Such differences in urine
excretion of the unchanged drug could explain the lower
occurrence and abundance of atazanavir crystals in the
urine of patients by comparison with indinavir-treated
patients. Marinescu et al. show atazanavir solubility in
urine and the time to crystallization decrease, as urine is
alkalized at pH>6 [52]. Among their 98 patients, 9 experi-
enced nephrolithiasis while under atazanavir therapy.
Among them, 3 (33%) had atazanavir crystals in their urine.
In contrast, none of the other patients had atazanavir
crystalluria. Recently, Gervasoni et al. showed that HIV
patients treated with atazanavir who experienced neph-
rolithiasis had an atazanavir plasma concentration four
times higher than patients without stones [53]. The study
by Hamada et al. revealed signiﬁcant differences in bili-
rubin concentrations in patients when they had renal colic,
suggesting that individuals with a slow metabolism of
atazanavir would have a greater incidence of lithiasis [54].
A multivariate analysis by Rusconi et al. showed a signif-
icant association between atazanavir-induced nephrolithiasis
and changes in the single-nucleotide polymorphism at
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Fig. 6. Kidney biopsy containing atazanavir crystals. A: Optical image; B: IR map; C: IR spectrum of atazanavir with the characteristic peaks (3428, 1722, 1529,
1053 cm1) in a protein matrix (kidney tissue); D: Electronic images of atazanavir crystals obtained by SEM.
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1A-30 region [55], which suggests a special sensitivity of some
patients to kidney side effects induced by atazanavir.4. Conclusion
At least 1.6% of urolithiasis are drug-induced in France, a
frequency likely underestimated. In 2.16% of renal biopsies
examined in our laboratory, we found drug crystals or drug-
induced deposits. The precise identiﬁcation of crystal de-
posits in the renal tissue may be essential for the diagnosis
of an unexplained renal failure. Clearly, in foscarnet-induced
acute renal failure, several types of crystals and different
locations of the crystals may be observed, suggesting
different risk factors involved in the drug precipitation inaddition to the dosage of the drug. Common histological
procedures clearly fail to identify crystal deposits accurately.
In most cases, light and polarizing microscopic examination
should be completed by physical methods. In our experi-
ence, the FTIR microscope and scanning electron micro-
scope are important tools for an accurate etiological
diagnosis. Taking into account the risk factors related to the
drug or the patient may help in most cases to prevent
crystallization of the drug and kidney injury.Acknowledgements
This work was supported by the Physics and Chemistry
Institutes of CNRS and by contracts ANR-09-BLAN-0120-02,
ANR-12-BS08-0022, ANR-13-JSV-10010-01, convergence
V. Frochot et al. / C. R. Chimie 19 (2016) 1565e15721572UPMC CVG1205 and CORDDIM-2013-COD130042. The au-
thors are grateful to the Soleil SR Facility for beam time
allocation (proposal numbers, SMIS- 20130016, SMIS-
20120070, SMIS-20110084, SMIS-20100566, and SMIS-
20100039), which allowed them to start this research.
References
[1] F. Ghane Shahrbaf, F.J. Assadi, J. Ren. Inj. Prev. 4 (2015) 57.
[2] T.D. Nolin, J. Himmelfarb, Handb. Exp. Pharmacol. 196 (2010) 111.
[3] G.S. Pazhayattil, A.C. Shirali, Int. J. Nephrol. Renov. Dis. 7 (2014)
457.
[4] M. Daudon, P. Jungers, Drugs 64 (2004) 245.
[5] D.K. Dhodi, S.B. Bhagat, D. Pathak, S.B. Patel, Int. J. Basic Clin. Phar-
macol. 3 (4) (2014) 591.
[6] C. Glanzmann, B. Frey, P. Vonbach, C.R. Meier, Pediatr. Nephrol. 31
(2016) 145.
[7] L. Ferreira da Silva Pinto Neto, B.R. Bassetti, I.H. Valvassoura Fraga,
C. Rocio Oliveira Santos, P. Daher Ximenese, A.E. Miranda, Braz. J.
Infect. Dis. 20 (2016) 14.
[8] A. Wong-Beringer, J. Joo, E. Tse, P. Beringer, Intern. J. Antimicrob.
Agents 37 (2011) 95.
[9] P. Balakumar, A. Rohilla, A. Thangathirupathi, Pharmacol. Res. 62
(2010) 179.
[10] S. Omar RabahSaudi, J. Biol. Sci. 17 (2010) 105.
[11] N. Pabla, Z. Dong, Kidney Int. 73 (2008) 994.
[12] A. Myint Thu, K. Poovorawan, C. Kittitrakul, A. Nontprasert,
N. Sriboonvorakul, W. Phumratanaprapin, P. Tangkijvanich,
W. Leowattana, P. Wilairatana, BMC Pharmacol. Toxicol. 16 (2015)
38.
[13] M. Kass, A.E. Kolker, M. Gordon, et al., Ophtalmology 88 (1981) 261.
[14] K.G. Hufnagel, S.N. Khan, J.D. Penn, et al., Pediatrics 70 (1982) 360.
[15] S.J. Wallace, Drug Sat. 15 (1996) 378.
[16] D. Bazin, M. Daudon, J. Phys. D. Appl. Phys. 45 (2012) 383001.
[17] D. Bazin, M. Daudon, C. Combes, C. Rey, Chem. Rev. 112 (2012) 5092.
[18] A. Dessombz, D. Bazin, P. Dumas, C. Sandt, J. Sule-Suso, M. Daudon,
PLoS ONE 6 (2011) e28007.
[19] Q.D. Nguyen, M. Daudon, Infrared and Raman Spectra of Calculi,
Elsevier, Paris, 1997.
[20] F. Cohen-Solal, J. Abdelmoula, M.P. Hoarau, P. Jungers, B. Lacour,
M. Daudon, Therapie 56 (2001) 743.
[21] R.S. Grifﬁth, Rev. Infect. Dis. 3 (S200) (1981) 20.
[22] R.B. Wallace, J. Wactawski-Wende, M.J. O'Sullivan, J.C. Larson,
B. Cochrane, M. Gass, K. Masaki, Am. J. Clin. Nutr. 94 (2011) 270.
[23] C.S. Crumpacker, Am. J. Med. 92 (1992) 3S.
[24] D. Boutolleau, A. Canestri, S. Burrel, M. Wirden Seang, C. Clavel-
Osorio, A.G. Marcelin, C. Katlama, H. Agut, J. Clin. Virol. 54 (2012)
194.
[25] V. Tischler, M.M. Schuurmans, A. Boehler, A. Gaspert, J. Hear.
Transpl. 31 (2012) 1037.
[26] G. Nyberg, C. Svalander, I. Blohme, H. Persson, Transpl. Int. 2 (1989)
223.
[27] D.T. Jayaweera, Drug Saf. 16 (1997) 258.
[28] G. Deray, F. Martinez, C. Katlama, B. Levaltier, H. Beauﬁls, M. Danis,
M. Rozenheim, A. Baumelou, E. Dohin, M. Gentilini, et al., Am. J.
Nephrol. 9 (1989) 316.
[29] A. Wallin, A. Ryrfeldt, Toxicol. in vitro 9 (1995) 237.[30] M.A. Jacobson, J.G. Gambertoglio, F.T. Aweeka, D.M. Causey,
A.A. Portale, J. Clin. Endocrinol. Metab. 72 (1991) 1130.
[31] L. Maurice-Estepa, M. Daudon, C. Katlama, C. Jouanneau,
V. Sazdovitch, B. Lacour, H. Beauﬁls, Am. J. Kidney Dis. 32 (1998)
392.
[32] H. Beauﬁls, G. Deray, C. Katlama, E. Dohin, D. Henin, V. Sazdovitch,
C. Jouanneau, Lancet 336 (1990) 755.
[33] D. Bazin, M. Daudon, Ann. Biol. Clin. 73 (2015) 517.
[34] K.T. Tashima, J. Horowitz, S. Rosen, New Engl. J. Med. 336 (1997)
138.
[35] M. Daudon, L. Estepa, J.-P. Viard, D. Joly, P. Jungers, Lancet 349
(1997) 1294.
[36] F. Martinez, H. Mommeja-Marin, L. Estepa-Maurice, H. Beauﬁls,
M. Bochet, M. Daudon, G. Deray, C. Katlama, Nephrol. Dial. Transpl.
13 (1998) 750.
[37] G.J. Wirth, J. Teuscher, J.D. Graf, C.E. Iselin, Urol. Res. 34 (2006)
288e289.
[38] H. Izzedine, M.A. Valantin, M. Daudon, H. Ait Mohand, F. Caby,
C. Katlama, AIDS 21 (2007) 1992 (letter).
[39] A. Jafari, H. Khalili, S. Dashti-Khavidaki, Eur. J. Clin. Pharmacol. 70
(2014) 1029.
[40] M. Zaidan, F.-X. Lescure, I. Brocheriou, S. Dettwiler, J.-B. Guiard-
Schmid, J. Pacanowski, E. Rondeau, G. Pialoux, P.-M. Girard,
P. Ronco, E. Plaisier, Clin. J. Am. Soc. Nephrol. 8 (2013) 930.
[41] J.C. Wasmuth, I. Lambertz, E. Voigt, M. Vogel, C. Hoffmann, D. Burger,
J.K. Rockstroh, Eur. J. Clin. Pharmacol. 63 (2007) 901.
[42] U.C. Brewster, M.A. Perazella, Am. J. Kidney Dis. 44 (2004) e81.
[43] H. Izzedine, M.B. M'Rad, A. Bardier, M. Daudon, D. Salmon, AIDS 21
(2007) 2357.
[44] L.F. Lopez-Cortes, Enferm. Infecc. Microbiol. Clin. 26 (S17) (2008) 2.
[45] Dictionnaire VIDAL, Vidal France, 2016.
[46] H.R. Chang, P.M. Pella, N. Engl. J. Med. 355 (2006) 2158.
[47] C. Couzigou, M. Daudon, J.-L. Meynard, F. Borsa-Lebas, D. Higueret,
L. Escaut, D. Zucman, J.-Y. Liotier, J.-L. Quencez, K. Asselah, T. May,
D. Neau, D. Vittecoq, Clin. Infect. Dis. 45 (2007) e105.
[48] K.M. Chan-Tack, M.M. Truffa, K.A. Struble, D.B. Birnkrant, AIDS 21
(2007) 1215.
[49] J.B. Kopp, K.D. Miller, J.A. Mican, I.M. Feuerstein, E. Vaughan,
C. Baker, L.K. Pannell, J. Falloon, Ann. Intern. Med. 127 (1997) 119.
[50] V. de Lastours, E. Silva, M. Daudon, et al., Intersci. Conf. Antimicrob.
Agent Chemother. 9 (2012) H889.
[51] S. Di Giambenedetto, M. Fabbiani, M. Colaﬁgli, N. Ciccarelli, S. Farina,
L. Sidella, A. D'Avino, A. Mondi, A. Cingolani, E. Tamburrini, R. Murri,
P. Navarra, R. Cauda, A. De Luca, J. Antimicrob. Chemother. 68 (2013)
1364.
[52] C.I. Marinescu, M. Leyes, M.A. Ribas, M. Pe~naranda, J. Murillas,
A.A. Campins, L. Martin-Pena, B. Barcelo, C. Barcelo-Campomar,
F. Grases, G. Frontera, M. Riera Jaume, AIDS Res. Treat. 1155 (2015)
106954.
[53] C. Gervasoni, P. Meraviglia, D. Minisci, L. Ferraris, A. Riva,
S. Landonio, V. Cozzi, N. Charbe, L. Molinari, G. Rizzardini,
E. Clementi, M. Galli, D. Cattaneo, PLoS ONE (2015) 1, http://
dx.doi.org/10.1371/journal.pone.0123670, 15 April.
[54] Y. Hamada, T. Nishijima, K. Watanabe, H. Komatsu, K. Tsukada,
K. Teruya, H. Gatanaga, Y. Kikuchi, S. Oka, Clin. Infect. Dis. 55 (2012)
1262.
[55] S. Rusconi, R. Gagliardini, S. Falvella, et al., in: Proceedings of the
14th European AIDS Conference, Brussels, 16e19 October 2013.
